Preliminary efficacy trial of Cymelarsan in mice artificially infected with Trypanosoma brucei brucei isolated from a dog in Zambia.
An efficacy trial of Cymelarsan on a Zambian strain of Trypanosoma brucei brucei was done. Twenty-five male mice were infected intraperitoneally with 10(6) of T. b. brucei isolated from a dog. Five groups of 5 mice were treated with 0 (control), 0.25, 0.5, 1.0 and 2.0 mg/kg Cymelarsan, respectively. The target was to achieve aparasitaemia for 30 days post-treatment, euthanising those that remained parasitaemic or relapsed before then. The 0.25 and 0.5 mg/kg groups remained parasitaemic although the parasitaemic levels were reduced. The 1.0 mg/kg group had a proportion of aparasitaemic mice. However, all mice in the 2.0 mg/kg group remained aparasitaemic until day 20 when 2 mice relapsed. These results suggested that more than 2.0 mg/kg was required to eliminate this strain.
D000818:Animals; D001152:Arsenicals / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D014344:Trypanocidal Agents / Q000627:therapeutic use*; D014346:Trypanosoma brucei brucei; D014353:Trypanosomiasis, African / Q000188:drug therapy / Q000662:veterinary*; D015024:Zambia
D001152:Arsenicals; D014344:Trypanocidal Agents; C062789:melaminylthioarsenate